Cocrystal Pharma (NASDAQ: COCP) is one of 702 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Cocrystal Pharma to related businesses based on the strength of its analyst recommendations, valuation, profitability, dividends, institutional ownership, earnings and risk.
This table compares Cocrystal Pharma and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cocrystal Pharma Competitors||-3,753.67%||-190.15%||-31.95%|
Insider & Institutional Ownership
10.6% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 43.8% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.8% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 15.3% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a summary of recent ratings and price targets for Cocrystal Pharma and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cocrystal Pharma Competitors||7220||19676||37552||1506||2.51|
As a group, “Pharmaceutical preparations” companies have a potential upside of 45.71%. Given Cocrystal Pharma’s rivals higher probable upside, analysts plainly believe Cocrystal Pharma has less favorable growth aspects than its rivals.
Risk and Volatility
Cocrystal Pharma has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500. Comparatively, Cocrystal Pharma’s rivals have a beta of 0.41, indicating that their average share price is 59% less volatile than the S&P 500.
Valuation and Earnings
This table compares Cocrystal Pharma and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cocrystal Pharma||$6.56 million||-$48.17 million||-15.00|
|Cocrystal Pharma Competitors||$1.95 billion||$238.24 million||-1.50|
Cocrystal Pharma’s rivals have higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
About Cocrystal Pharma
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.